Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfadoxine + pyrimethamine is an oral fixed-dose antimalarial combination comprising the long-acting sulfonamide sulfadoxine and the antifolate pyrimethamine. Sulfadoxine competitively inhibits *Plasmodium* dihydropteroate synthase and pyrimethamine inhibits *Plasmodium* dihydrofolate reductase, producing sequential blockade of parasite folate synthesis and synergistic inhibition of nucleic-acid synthesis. It is used for treatment and prevention of malaria, including intermittent preventive treatment in pregnancy and, with amodiaquine, seasonal malaria chemoprevention in eligible endemic-area populations; resistance associated with parasite *dhps* and *dhfr* mutations limits effectiveness in many settings. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18557slr015_fansidar_lbl.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfadoxine + pyrimethamine.